Emory University School of Medicine Hematology and Medical Oncology

Topics

• Multiple Myeloma Research and Treatments 457
• Lymphoma Diagnosis and Treatment 223
• Head and Neck Cancer Studies 194
• Cancer Immunotherapy and Biomarkers 133
• Blood groups and transfusion 112
• Hematopoietic Stem Cell Transplantation 110
• CAR-T cell therapy research 108
• Neuroendocrine Tumor Research Advances 106
• Acute Myeloid Leukemia Research 90
• Lung Cancer Treatments and Mutations 87
• Breast Cancer Treatment Studies 78
• Cytokine Signaling Pathways and Interactions 72

Most cited

1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

   The New England journal of medicine · 2021 · 2,130 citations · Sagar Lonial

2. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.

   International journal of molecular sciences · 2022 · 1,007 citations · Maroun Zerdan

3. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

   The New England journal of medicine · 2021 · 1,378 citations · Kevin Kalinsky

4. Teclistamab in Relapsed or Refractory Multiple Myeloma.

   The New England journal of medicine · 2022 · 1,060 citations · Ajay Nooka

5. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

   Lancet (London, England) · 2024 · 321 citations · Daniel Halperin

6. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

   The New England journal of medicine · 2023 · 653 citations · Ajay Nooka